

1 **Supplemental Figures and Tables**

2


shRNA	Sequence	Cells
TCRN000000531	CCGGCCACGATTTGACCCTCAACTTCTCGAGAAGTTGAGGGTCAAATCGTGGTTTTT	THP-1
TCRN0000005321	CCGGCTGTGTAGTGTGCCCTCATATCTCGAGATATGAGGGCACACTACACAGTTTTT	THP-1
TCRN0000005320	CCGGCAATTACACTTCGACTCTCAACTCGAGTTGAGAGTCGAAGTGTAATTGTTTTT	THP-1
TCRN0000005319	CCGGTGGATCAACATTCTTCTAACTCGAGTTAGAAGAGAATGTTGATCCATTTTT	THP-1
TRCN0000066928	CCGGGCGACACAATTCAGGGAGAACTCGAGTTTCTCCCTGAATTGTGTCGCTTTTTG	RAW
TRCN0000066930	CCGGCCAAACATCGTCTCACCGTATCTCGAGATACGGTGAGACGATGTTTGGTTTTTG	RAW
TRCN0000066932	CCGGCAATTAGACTTCAGCACTCAACTCGAGTTGAGTGCTGAAGTCTAATTGTTTTTG	RAW
TRCN0000066931	CCGGCCAACCTCGTTTCAAGTCAGAACTCGAGTTCTGACTTGAAACGAGTTGGTTTTTG	RAW
SHC016V	CCGGGCGCGATAGCGCTAATAATTTCTCGAGAAATTATTAGCGCTATCGCGCTTTTT	Nontarget shRNA

3 **Supplemental Table 1. Identity and sequence of Dectin-1-targeting shRNA constructs.**

4

5

6



7

8 **Supplemental Figure 1. Agonistic effect of purified *C. albicans* β -glucan on primary human**

9 **PBMCs.** Relative levels of the indicated cytokine produced in response to no treatment vs.

10 treatment with 10 μ g/ml of the highly purified *C. albicans* β -glucan. Results demonstrate mean

11 and individual values of replicates from two separate experiments.

12